Establishment Labs Hits an Inflection: U.S. Launch and Minimally Invasive Platform Drive Profitability
Revenue growth of 45% and three consecutive positive EBITDA quarters set the stage for cash flow positivity.
ESTA · Earnings Call · 2026-05-06
The Inflection Point
Establishment Labs is no longer a story about promise — it is a story about execution. Q1 2026 revenue of $59.9 million grew 45% year-over-year, with the U.S. business surging 216% to $19.6 million. The company delivered its third consecutive quarter of positive adjusted EBITDA at $1.2 million, and management raised full-year guidance to $266.5–268.5 million. As CEO Filippo Caldini put it, “Q1 2026 was a strong start to the year with $59.9 million in revenue and adjusted EBITDA of $1.2 million, representing revenue growth of 45% over Q1 2025.” — Filippo Caldini, Chief Executive Officer · 2026-05-06 The U.S. launch is accelerating: “The U.S. business continued to outperform with $19.6 million of revenue, a growth of 216% over Q1 2025.” — Filippo Caldini, Chief Executive Officer · 2026-05-06 Critically, the company is now guiding to be adjusted EBITDA positive in every quarter of 2026 and expects to reach cash flow positive in the back half of the year — a milestone that would transform the investment story.Minimally Invasive Goes Mainstream
The core driver is the minimally invasive platform, which combines minimal anesthesia, smaller scars, and a faster recovery to pull new patients into the category. The platform generated $9.1 million in Q1 revenue, and management now expects it to exceed $35 million for the year, up from the prior $30 million guidance. The company is seeing real market expansion:This is not just a premium niche: in the U.S., 15% of Preserve patients had not previously considered breast augmentation. The company boasts an industry-low complication rate of under 1% from its global warranty data, a key trust builder that supports the premium pricing. The momentum in the U.S. is tangible — the company surpassed 1,700 accounts and 260 certified surgeons in Q1, well ahead of its internal 200-surgeon goal for the full year. As CFO Sandra Harris noted, “We also expect to be adjusted EBITDA positive in each quarter of 2026.” — Cassandra Harris, Chief Financial Officer · 2026-05-06 The new long term agreement discussions with silicone supplier NuSil and the recent debt refinancing with Oaktree provide the financial flexibility to scale without dilution. The company's previous calls set the stage for this inflection. In February 2026, management stated, “We're seeing that benefit. And we think that that's going to continue to be a key driver. It's going to be a bigger part of our business as we go throughout this year as well as next.” — Filippo Caldini, Chief Executive Officer · 2026-02-24 And back in November 2025, they highlighted the U.S. momentum: “Clearly, a lot of momentum in the business heading into the fourth quarter.” — Filippo Caldini, Chief Executive Officer · 2025-11-05 The consistency of the narrative suggests this is not a one-off — it is a structural shift.The launch of minimally invasive techniques into any specialty almost always dramatically increases the market.